Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer.
BACKGROUND
Despite identification of the major genes and pathways involved in the development of colorectal cancer (CRC), it has become obvious that several steps in these pathways might be bypassed by other as yet unknown genetic events that lead towards CRC. Therefore we wanted to improve our understanding of the genetic mechanisms of CRC development.


METHODS
We used microarrays to identify novel genes involved in the development of CRC. Real time PCR was used for mRNA expression as well as to search for chromosomal abnormalities within candidate genes. The correlation between the expression obtained by real time PCR and the presence of the KRAS mutation was investigated.


RESULTS
We detected significant previously undescribed underexpression in CRC for genes SLC26A3, TPM1 and DCN, with a suggested tumour suppressor role. We also describe the correlation between TPM1 and DCN expression and the presence of KRAS mutations in CRC. When searching for chromosomal abnormalities, we found deletion of the TPM1 gene in one case of CRC, but no deletions of DCN and SLC26A3 were found.


CONCLUSIONS
Our study provides further evidence of decreased mRNA expression of three important tumour suppressor genes in cases of CRC, thus implicating them in the development of this type of cancer. Moreover, we found underexpression of the TPM1 gene in a case of CRCs without KRAS mutations, showing that TPM1 might serve as an alternative path of development of CRC. This downregulation could in some cases be mediated by deletion of the TPM1 gene. On the other hand, the correlation of DCN underexpression with the presence of KRAS mutations suggests that DCN expression is affected by the presence of activating KRAS mutations, lowering the amount of the important tumour suppressor protein decorin.
Mlakar
Vid
V
Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. vid.mlakar@mf.uni-lj.si
Berginc
Gasper
G
Volavsek
Metka
M
Stor
Zdravko
Z
Rems
Miran
M
Glavac
Damjan
D
D015179:Colorectal Neoplasms / Q000235:genetics* / Q000378:metabolism; D058575:Decorin; D016326:Extracellular Matrix Proteins / Q000235:genetics* / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009154:Mutation; D011509:Proteoglycans / Q000235:genetics* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D014335:Tropomyosin / Q000235:genetics* / Q000378:metabolism; D018631:ras Proteins / Q000235:genetics* / Q000378:metabolism
C546878:DCN protein, human; D058575:Decorin; D016326:Extracellular Matrix Proteins; C117307:KRAS protein, human; D011509:Proteoglycans; D011518:Proto-Oncogene Proteins; C490775:TPM1 protein, human; D014335:Tropomyosin; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins
Adv Cancer Res. 2002;84:57-80
11883532
Cell Tissue Res. 1999 May;296(2):221-7
10382266
Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7039-43
8346214
Cell Calcium. 2000 Aug;28(2):83-96
10970765
Nature. 1988 Nov 17;336(6196):244-6
3194009
Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8
12093899
J Biol Chem. 1996 Aug 2;271(31):18961-5
8702560
J Biol Chem. 2006 Sep 8;281(36):26408-18
16835231
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6745-50
10359783
Life Sci. 2004 Jan 16;74(9):1065-70
14687647
Cell Cycle. 2006 Oct;5(19):2183-6
16969097
Cancer Res. 2001 Apr 1;61(7):3124-30
11306497
Endocr Rev. 2003 Dec;24(6):719-36
14671000
Clin Cancer Res. 1998 Aug;4(8):1857-63
9717812
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7016-20
7624361
Oncogene. 1996 Aug 1;13(3):537-45
8760295
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27
15000146
Nat Genet. 1996 Nov;14(3):316-9
8896562
Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S57-64
15309516
Cancer Res. 2002 Sep 1;62(17):5083-8
12208765
Hum Mol Genet. 1994 May;3(5):801-7
7521710
Hum Mutat. 1993;2(5):404-14
8257994
Cancer Res. 1996 Aug 15;56(16):3634-7
8705997
Hum Mol Genet. 2001 Apr;10(7):721-33
11257105
Cancer Res. 2006 Apr 15;66(8):3992-5
16618717
Life Sci. 2002 May 3;70(24):2829-55
12269397
Cancer Res. 1990 Apr 1;50(7):2105-12
2317800
Oncogene. 2002 Jul 18;21(31):4855-62
12101425
World J Gastroenterol. 2007 Jul 28;13(28):3784-91
17657831
Int J Cancer. 1996 Feb 20;69(1):38-43
8600057
Am J Physiol. 1999 Jan;276(1):G7-G13
9886972
J Toxicol Environ Health A. 2001 Mar 9;62(5):333-47
11261896
J Pathol. 2000 Mar;190(4):412-6
10699988
Br J Cancer. 2007 Apr 23;96(8):1166-9
17375050
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
Med Sci Monit. 2008 Oct;14(10):CR530-5
18830193
Int J Cancer. 2007 Nov 1;121(9):2005-12
17640062
Genome Biol. 2006;7(3):R19
16542501
Proc Natl Acad Sci U S A. 1993 May 1;90(9):4166-70
7683425
Virchows Arch. 2008 Nov;453(5):417-31
18802721
Gut. 2005 Sep;54(9):1283-6
15843421
Oncogene. 1998 Feb 5;16(5):681-4
9482116